首页> 外文期刊>International journal of hematology >Excellent outcome of allogeneic bone marrow transplantation for Fanconi anemia using fludarabine-based reduced-intensity conditioning regimen
【24h】

Excellent outcome of allogeneic bone marrow transplantation for Fanconi anemia using fludarabine-based reduced-intensity conditioning regimen

机译:基于氟达拉滨的低强度调理方案,同种异体骨髓移植治疗Fanconi贫血的优异结果

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Fanconi anemia (FA) is a disorder characterized by developmental anomalies, bone marrow failure and a predisposition to malignancy. It has recently been shown that hematopoietic stem cell transplantation using fludarabine (FLU)-based reduced-intensity conditioning is an efficient and quite safe therapeutic modality. We retrospectively analyzed the outcome of bone marrow transplantation (BMT) in eight patients with FA performed in two institutes between 2001 and 2011. There were seven females and one male with a median age at diagnosis = 4.5 years (range 2-12 years). The constitutional characteristics associated with FA, such as developmental anomalies, short stature and skin pigmentation, were absent in three of the patients. One patient showed myelodysplastic features at the time of BMT. All patients received BMT using FLU, cyclophosphamide (CY) and rabbit antithymocyte globulin (ATG) either from a related donor (n = 4) or an unrelated donor (n = 4). Acute graft-versushost disease (GVHD) of grade I developed in one patient, while chronic GVHD was not observed in any patient. All patients are alive and achieved hematopoietic recovery at a median follow-up of 72 months (range 4-117 months). BMT using FLU/low-dose CY/ATG -based regimens regardless to the donor is a beneficial therapeutic approach for FA patients.
机译:范可尼贫血(FA)是一种以发育异常,骨髓衰竭和恶性肿瘤易感性为特征的疾病。最近显示,使用基于氟达拉滨(FLU)的降低强度调节的造血干细胞移植是一种有效且相当安全的治疗方式。我们回顾性分析了2001年至2011年间在两家机构进行的8例FA患者的骨髓移植(BMT)的结果。女性7例,男性1例,诊断中位年龄为4.5岁(2-12岁)。其中三例患者缺乏与FA相关的体质特征,例如发育异常,身材矮小和皮肤色素沉着。一名患者在BMT时表现出骨髓增生异常。所有患者均从相关供体(n = 4)或非相关供体(n = 4)接受了使用FLU,环磷酰胺(CY)和兔抗胸腺细胞球蛋白(ATG)的BMT。一名患者发生了I级急性移植物抗宿主病(GVHD),而任何患者均未观察到慢性GVHD。所有患者均存活,并在中位随访72个月(范围4-117个月)时达到了造血恢复。不论捐献者如何,使用基于FLU /低剂量CY / ATG的方案进行BMT对FA患者都是一种有益的治疗方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号